Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.36 |
| ▸ | MGAM | O43451 | 1/20 | 0.36 |
| ▸ | SI | P14410 | 1/20 | 0.36 |
| ▸ | MGAM2 | Q2M2H8 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.33 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.32 |
| ▸ | PGR | P06401 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10654873 | 0.84 | CYP1A2 (0.47) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL1935858 | 0.79 | CA12 (0.43) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL10653733 | 0.73 | GAA (0.48) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL1506652 | 0.71 | CYP1A2 (0.39) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL28647620 | 0.70 | CYP1A2 (0.48) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL66021 | 0.69 | ALDH1A1 (0.54) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL4788929 | 0.69 | MEN1 (0.60) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL29191663 | 0.69 | CYP1A2 (0.44) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL9685398 | 0.68 | GAA (0.52) | CYP1A2GAAMGAMSIMGAM2 | |
| SCHEMBL11342514 | 0.68 | CYP1A2 (0.42) | CYP1A2GAAMGAMSIMGAM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110059898-A1 | PRO-OXIDANT ANTI-CANCER COMPOUNDS | CANCURE LIMITED (AU) | 2011-03-10 | — | — | US | claimed |
| EP-2063884-A1 | PRO-OXIDANT ANTI-CANCER COMPOUNDS | Ralph, John Stephen (AU) | 2009-06-03 | — | — | EP | claimed |
| WO-2008031171-A1 | PRO-OXIDANT ANTI-CANCER COMPOUNDS | UNIV GRIFFITH (AU) | 2008-03-20 | — | — | WO | claimed |
| EP-2063884-B1 | PRO-OXIDANT ANTI-CANCER COMPOUNDS | RALPH STEPHEN JOHN (AU) | 2014-08-13 | — | — | EP | disclosed |
| US-8410056-B2 | Pro-oxidant anti-cancer compounds | CANCURE LIMITED (AU) | 2013-04-02 | — | — | US | disclosed |
| US-8410056-B2 | Pro-oxidant anti-cancer compounds | CANCURE LIMITED (AU) | 2013-04-02 | — | — | US | disclosed |
| US-20110059898-A1 | PRO-OXIDANT ANTI-CANCER COMPOUNDS | CANCURE LIMITED (AU) | 2011-03-10 | — | — | US | disclosed |
| US-20110059898-A1 | PRO-OXIDANT ANTI-CANCER COMPOUNDS | CANCURE LIMITED (AU) | 2011-03-10 | — | — | US | disclosed |
| EP-2063884-A1 | PRO-OXIDANT ANTI-CANCER COMPOUNDS | Ralph, John Stephen (AU) | 2009-06-03 | — | — | EP | disclosed |
| WO-2008031171-A1 | PRO-OXIDANT ANTI-CANCER COMPOUNDS | UNIV GRIFFITH (AU) | 2008-03-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059898-A1 | PRO-OXIDANT ANTI-CANCER COMPOUNDS | PRDX5, MT-ND2, UQCRC2 | CYP1A2 790/4885GAA 4373/4885MGAM 3411/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.